MediGene Receives Further European Patent on EndoTAG(TM)-1
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Patent renews coverage and expands the protected territoryMartinsried/Munich, October 5, 2009. The biotech company MediGene AG(Frankfurt: MDG, Prime Standard, TecDAX) has obtained an extensivepatent (no. 1530465) from the European Patent Office on themanufacturing process for the drug candidate EndoTAG(TM)-1. Thepatent protects the manufacturing process used for EndoTAG(TM)-1,including the drying step applied, products manufactured by thespecified steps, products with identical properties, as well asfurther specified dried cationic liposomal compounds. The term of thepatent "Method of producing a cationic liposomal preparationcomprising a lipophilic compound" ends on June 26, 2023.Dr. Frank Mathias, Chief Executive Officer of MediGene AG: "This newpatent is extremely important for MediGene and for thecommercialization of EndoTAG(TM)-1. In addition to the good patentprotection which we already possess for the EndoTAG(TM) technology ingeneral and for EndoTAG(TM)-1 in particular, the manufacturingprocess and the dried formulation of our drug candidate are now alsopatented. Overall patent protection is renewed for the product initself, and the protected territory has been enlarged by a number ofEuropean countries. Whereas EndoTAG(TM)-1 is administered in the formof a suspension, the drug will be commercialized in the form of adried product, so the patent represents a major progress toward ourfuture plans for commercialization."About EndoTAG(TM)-1: The drug candidate EndoTAG(TM)-1 selectivelyattacks blood vessels needed for the growth of tumors. It is a novelcombination of positively charged liposomes - minute globules oflipid molecules - and the embedded active substance paclitaxel.EndoTAG(TM)-1 is targeted to the negatively charged cells that arelining newly formed tumor blood vessels. Thus only tumor bloodvessels are attacked without any harm to those in healthy tissue. Atthe same time EndoTAG(TM)-1 inhibits the development of new bloodvessels, thus suppressing further tumor growth. The drug candidatehas obtained orphan drug designation for Europe and the USA, grantingbenefits in the development and commercialization of drugs for thetreatment of rare diseases.In October 2008 MediGene reported positive results obtained in aclinical phase II trial of the drug candidate EndoTAG(TM)-1 for thetreatment of pancreatic carcinoma. Since 2007, MediGene has beenconducting another clinical phase II trial in the indication triplereceptor-negative breast cancer, the results of which are expected inthe first six months of 2010.This press release contains forward-looking statements that involverisks and uncertainties. The forward-looking statements containedherein represent the judgment of MediGene as of the date of thisrelease. These forward-looking statements are no guarantees forfuture performance, and the forward-looking events discussed in thispress release may not occur. MediGene disclaims any intent orobligation to update any of these forward-looking statements.MediGene(TM) and EndoTAG(TM) are trademarks of MediGene AG. Thistrademark may be held or licensed for specific countries. - ends -MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard,TecDAX) biotechnology company located in Martinsried/Munich, Germany,with subsidiaries in Oxford, UK and San Diego, USA. MediGene is thefirst German biotech company to have drugs on the market, which arebeing distributed by partner companies and has several drugcandidates in clinical development, two of which provide significantsales potential. In addition, the company has numerous projects inresearch and pre-clinical development and possesses innovativeplatform technologies. MediGene focuses on the research anddevelopment of novel drugs for the treatment of cancer and autoimmunediseasesContact MediGene AGE-mail: investor(at)medigene.comFax: +49 - 89 - 85 65 - 2920Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 8565 - 3324Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946 --- End of Message ---MediGene AGLochhamer Strasse 11 Martinsried / München GermanyWKN: 502090; ISIN: DE0005020903 ; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 05.10.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 6552
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 483 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene Receives Further European Patent on EndoTAG(TM)-1"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
